|Ovarian cancers in women aged 20+, with area representing relative incidence and color representing 5-year relative survival rate. Serous cystadenocarcinoma is labeled at bottom left.|
Most commonly, the primary site of serous cystadenocarcinoma is the ovary. Rare occurrence in the pancreas has been reported, although this is not typical, with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous cystadenoma.
- Kosary, Carol L. (2007). "Chapter 16: Cancers of the Ovary" (PDF). In Baguio, RNL; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J (eds.). SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. SEER Program. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 133–144.
- ing JC. Ng TT. White SC. Cortina G. Reber HA. Hines OJ. Journal of Gastrointestinal Surgery. 13(10):1864-8 (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Cite journal requires
- Friebe V, Keck T, Mattern D, et al. (August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182–7. doi:10.1097/01.mpa.0000167001.89018.3c. PMID 16025006.